RXDX - Prometheus Biosciences had other bidders besides Merck - report
2023-04-17 09:47:58 ET
- Prometheus Biosciences ( NASDAQ: RXDX ) had other bidders for the company besides Merck ( NYSE: MRK ).
- There was a competition to purchase Prometheus ( RXDX ), according to CNBC's David Faber, who cited people familiar. The $10.8 billion deal appears to be the largest dollar price of any company that is only out of a Phase 2.
- Prometheus Biosciences jumped ~70% on Monday after Merck ( MRK ) agreed to acquire the clinical-stage biotech for $10.8B in cash on Sunday to expand the pharma giant's focus on immunology .
For further details see:
Prometheus Biosciences had other bidders besides Merck - report